Pacira BioSciences, Inc. (PCRX)
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic
$25.39
-0.63%
Mkt Cap $1.09B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $200.33M | $196.87M | -1.73% | $0.85 | $0.57 | -32.94% | — | — |
| Q4 2025 Nov 6, 2025 | $201.93M | $179.52M | -11.10% | $0.65 | $0.70 | +7.69% | — | — |
| Q3 2025 Aug 5, 2025 | $182.38M | $181.10M | -0.70% | $0.72 | $0.74 | +2.78% | — | — |
| Q2 2025 May 8, 2025 | $187.48M | $168.92M | -9.90% | $0.57 | $0.62 | +8.77% | — | — |
| Q1 2025 Feb 27, 2025 | $185.38M | $187.25M | +1.01% | $0.78 | $0.91 | +16.67% | — | — |
| Q4 2024 Nov 6, 2024 | $179.48M | $168.57M | -6.08% | $0.72 | $0.79 | +9.72% | — | — |
| Q3 2024 Jul 30, 2024 | $172.50M | $178.02M | +3.20% | $0.73 | $0.89 | +21.92% | — | — |
| Q2 2024 May 7, 2024 | $165.35M | $167.12M | +1.07% | $0.64 | $0.62 | -3.13% | — | — |
| Q1 2024 Feb 29, 2024 | $181.66M | $181.24M | -0.23% | $0.89 | $0.89 | +0.00% | — | — |
| Q4 2023 Nov 2, 2023 | $179.77M | $163.93M | -8.81% | $0.84 | $0.72 | -14.29% | — | — |
| Q3 2023 Aug 2, 2023 | $174.60M | $169.47M | -2.94% | $0.81 | $0.78 | -3.70% | — | — |
| Q2 2023 May 3, 2023 | $158.84M | $160.34M | +0.94% | $0.60 | $0.53 | -11.67% | — | — |
| Q1 2023 Feb 28, 2023 | $171.94M | $171.96M | +0.01% | $0.80 | $0.80 | +0.00% | — | — |
| Q4 2022 Nov 3, 2022 | $168.33M | $167.47M | -0.51% | $0.73 | $0.64 | -12.33% | — | — |
| Q3 2022 Aug 3, 2022 | $170.64M | $169.41M | -0.72% | $0.85 | $0.51 | -40.00% | — | — |
| Q2 2022 May 4, 2022 | $159.72M | $157.99M | -1.09% | $0.74 | $0.64 | -13.51% | — | — |
| Q1 2022 Feb 24, 2022 | $156.29M | $159.19M | +1.86% | $0.83 | $0.97 | +16.87% | — | — |
| Q4 2021 Nov 3, 2021 | $140.49M | $127.72M | -9.09% | $0.66 | $0.72 | +9.09% | — | — |
| Q3 2021 Aug 3, 2021 | $131.94M | $135.59M | +2.77% | $0.76 | $0.77 | +1.32% | — | — |
| Q2 2021 May 4, 2021 | $118.63M | $119.03M | +0.33% | $0.59 | $0.53 | -10.17% | — | — |